Work

AML-1217: Ziftomenib Combined With Intensive Induction (7+3) for Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Long-Term Results From the KOMET-007 Trial

Year: 2026
Type: conference-abstract
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W7204713625
Cites:
Cited by:
Related to: